Valuation
54
NEIMETH · Neimeth International Pharmaceuticals Plc
Neutral Neutral Quality 4/5Distress proxy: 34.15 (Safe)
Compare with another stock →
Composite score
56.8
Tier: Neutral
Last close
₦8
As of latest snapshot
30-day ADV
₦8.4M
Liquidity signal
Market cap
₦34.61B
HealthCare
Financials
68
Technical
46
AI bottom line
Neimeth trades in line with peers at 35.2x P/E but commands a premium valuation multiple at 12.9x P/B versus 10.8x sector median, supported by above-median ROE of 35.9% and net margins of 12.4%. Execution risk centers on the newly approved ₦30 billion capital raise and de-leveraging the 3.47x debt/equity ratio while managing thin liquidity of ₦8.4M daily average volume.
Stock Snowflake 5-axis radar
Blue = NEIMETH. Gold dash = HealthCare median. Bigger area = better across the five research dimensions.
What the model is seeing
- Trades at P/E 35.2x — in line with HealthCare median of 35.2x.
- ROE of 35.9% — above HealthCare median of 31.9%.
- Below both 50-day (-15.8%) and 200-day (-1.0%) moving averages — sustained downtrend.
Risk flags
Thin liquidity — 30d ADV ≈ ₦8.4M
High leverage — Debt/Equity 3.5x
Price & trend
Close price with 50-day and 200-day moving averages, last 12 months.
Composite score history
How the model has rated this stock over the available history. Tier changes happen at 75 / 60 / 40.
Key metrics
Valuation
P/E ratio35.2x
P/B ratio12.9x
P/S ratio4.5x
EV/EBITDA17.2x
FCF yield4.3%
Financials
ROE35.9%
ROA7.0%
Net margin12.4%
FCF margin19.1%
Debt / Equity3.5x
Technical
Last close₦8
Above 50d MA-15.8%
Above 200d MA-1.0%
ADX (trend)53.6
RSI45.5
Dividend history 5 fiscal years shown
All amounts are gross of Nigeria's 10% withholding tax on dividends. Bonus ratios are 'new shares for shares held'.
Current yield: 0.86%
| FY | Interim DPS | Final DPS | Total cash | Bonus | Qualification | Payment |
|---|---|---|---|---|---|---|
| 2021 | — | ₦0.07 | ₦0.07 | — | — | 25 Mar 2022 |
| 2020 | — | ₦0.065 | ₦0.065 | — | — | 12 Mar 2021 |
| 2018 | — | — | — | 1 for 10 | — | — |
| 2016 | — | — | — | 1 for 10 | — | — |
| 2013 | — | ₦0.06 | ₦0.06 | — | — | — |
Peers in HealthCare
Closest names by composite score within the same sector. Click a symbol to open its detail page.
| Symbol | Composite | P/E | P/B | ROE | Tier |
|---|---|---|---|---|---|
| MECURE | 49.0 | 52.5x | 17.9x | 34.2% | Neutral |
| MORISON | 44.9 | 527.8x | 10.8x | 1.8% | Illiquid |
| FIDSON | 74.3 | 19.8x | 6.9x | 31.9% | Accumulate |
| MAYBAKER | 77.8 | 14.2x | 4.6x | 30.6% | Conviction Buy |
Recent news mentioning NEIMETH
NGX corporate disclosures NEIMETH · last 2
Plain-English summaries of every NGX filing for NEIMETH, generated from the underlying PDFs by Claude Haiku. Click "Read the filing" to open the official document.
AGM Notice
filed 29 Jun 2026
Neimeth International Pharmaceuticals passed 67th AGM resolutions on 25 June 2026. Key approval: Board authorized to raise an additional ₦30 billion in capital (shares, bonds, commercial papers), bringing total capital-raising authority to ₦50 billion, of which ₦2.44 billion already raised via rights issue, leaving ₦47.56 billion available for deployment.
AGM Notice
filed 18 Jun 2026
Neimeth International Pharmaceuticals filed notice of its 67th AGM (25 June 2026, virtual). Core item: shareholders will vote on new ₦30 billion capital-raising authorization, bringing total approval to ₦50 billion. Company has raised ₦2.44 billion via rights issue, leaving ₦47.56 billion unutilised. Register closes 15–19 June 2026.